IAS–USA From RT Mitsuyasu, MD, at San Francisco, CA: March 29, 2013, IAS-USA. Slide 1 of 31 Non-AIDS-Defining Cancers in HIV Ronald T. Mitsuyasu, MD Professor of Medicine University of California Los Angeles Director, UCLA Center for Clinical AIDS Research and Education
30
Embed
IAS–USA From RT Mitsuyasu, MD, at San Francisco, CA: March 29, 2013, IAS-USA. Slide 1 of 31 Non-AIDS-Defining Cancers in HIV Ronald T. Mitsuyasu, MD Professor.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
IAS–USAFrom RT Mitsuyasu, MD, at San Francisco, CA: March 29, 2013, IAS-USA.
Slide 1 of 31
Non-AIDS-Defining Cancers in HIV
Ronald T. Mitsuyasu, MDProfessor of Medicine
University of California Los AngelesDirector, UCLA Center for Clinical AIDS Research
and Education
Slide 2 of 31
From RT Mitsuyasu, MD, at San Francisco, CA: March 29, 2013, IAS-USA.
Age distribution of HIV-infected individuals living in the United States
• Compared to AA, HR 1.56 (CI, 1.78, 1.22) p=0.02– HAART was protective for ADC but not NADC
• OR 0.21, p<0.001– Lower most recent CD4 count– Smoking history; other lifestyle behaviors– History of Hepatitis B– Socioeconomic status and access to care
Crum-Cianflone AIDS 2009, 23:41-50Llibfre JM. Curr HIV Res 2009, 7;365-77Reekie J, Cancer 2010, 116;5306-15
Slide 18 of 31
From RT Mitsuyasu, MD, at San Francisco, CA: March 29, 2013, IAS-USA.
Aging Phenotype
• Increase CD8+ CD28- cells• Increase CD4+ CD28- cells• Shorten telomeres• Increased CD31- cells (esp on CD45RA+)• Increased CD56+ CD57+ cells• See this in both HIV+ individuals and
elderly HIV- individualsBoucher et al., Exp. Gerontol. 33:267, 1998Effros R et al., Aging and Infect Dis 47:542-53, 2008Rickabaugh T et al., PLoS One 6:16459, 2011
Slide 19 of 31
From RT Mitsuyasu, MD, at San Francisco, CA: March 29, 2013, IAS-USA.
ACS, NCI and USPSTF Cancer Screening Guidelines
• Cervical CA – begin within 3 yrs of 1st intercourse or 21 yo and q 1-2 yrs. If 30-70 and 3 normal Paps q3 yrs
• Prostate CA – discuss with MD at 50. DRE yearly and individualized PSA testing
• Breast CA – clinical breast exam q 3 yr 20-30, yearly at 40, yearly mammogram start age 50
• Colon CA – flex sig q 5yrs or colon q 10 yrs and FOBT yearly
• Others – periodic health exams after age 20, with health counseling and oral, skin, lymph nodes, testes, ovaries and thyroid exam
• Other tests based on family history, other known cancer risk exposures or known risk factors
Slide 20 of 31
From RT Mitsuyasu, MD, at San Francisco, CA: March 29, 2013, IAS-USA.
HIV Patient Screening
• Routine screening for HIV patients seems to be done LESS frequently than age-appropriate SOC screening for breast (67% vs 79%) and colon (56% vs 77.8%) and prostate biopsies– Preston-Martin. Prev Med 2002;31:316-92– Reinhold JP. Am J Gastroenterol 2005;100:1805-12– Hsiao W, Science World J 2009;9:102-8
• Concerns about higher false positive rate in HIV (eg, NLST found reduction in lung cancer mortality (20%) in older cigarette smokers) but also high false positive rates, which may be true in HIV as well
Slide 21 of 31
From RT Mitsuyasu, MD, at San Francisco, CA: March 29, 2013, IAS-USA.
Lung Cancer Screening• CT imaging for early detection of lung
cancer is controversial (N Engl J Med. 2011 Aug 4;365(5):395-409), and HIV+ may be at greater risk of developing lung cancer
• VA Aging Cohort substudy – prospective Examination of HIV Associated Lung Emphysema (EXHALE) 2009-10, smokers, 145 HIV+ and 125 HIV- convenience sample, 86% smokers, single CT to determine rate of abnormal findings
Sigel K et al. 19th CROI, Seattle, 2012, abst 907
Slide 22 of 31
From RT Mitsuyasu, MD, at San Francisco, CA: March 29, 2013, IAS-USA.
Lung Cancer ScreeningCharacteristic HIV+
(n=145) %HIV-
(n=126) %P-
value
Age, years (median) 54 42 0.1
Male 98 87 0.001
White/Black/Hispanic 14/70/17 20/64/16 0.41
Smoking: Current/former/never
65/21/14 61/21/18 0.8
Pack Years (median) 26 23 0.2
COPD, emphysema or chronic bronchitis
18 18 0.9
CD4 count (median) 425
Siegel K et al 19th CROI, Seattle, 2012, abstr 907
Slide 23 of 31
From RT Mitsuyasu, MD, at San Francisco, CA: March 29, 2013, IAS-USA.
Lung Cancer ScreeningFindings HIV+
(n=145) %HIV-
(n=126) %p- value
Nodules noted 50 46 0.6
Number nodules (median) 8 7 0.4
Lymphadenopathy 15 7 0.06
Suspicious for cancer 4 2 0.2
Emphysematous changes 40 30 0.07
Pleural effusion 0 1 0.3
Ground glass infiltrates 15 14 0.9
Bronchiectasis 6 6 0.8
Granulomas 24 18 0.2
Follow-up recommended* 23 29 0.3
Siegel K, et al, 19th CROI, Seattle, 2012, abst 907.*4 Lung cancer diagnoses, 3 HIV+ and 1 HIV- p=0.4
Slide 24 of 31
From RT Mitsuyasu, MD, at San Francisco, CA: March 29, 2013, IAS-USA.
Why is anogenital cancer important?• Cervical cancer is the most common cancer
in women worldwide and anal cancer is as common in MSM (75/100,000) as cervical cancer in unscreened populations of women (50-150/100,000 person-yr)
• Anal cancer particularly common in HIV+ MSM
• Anal cancer occurs in women as well• Anal cancer is one of several cancers whose
incidence in the HAART era is increasing, not decreasing
Slide 25 of 31
From RT Mitsuyasu, MD, at San Francisco, CA: March 29, 2013, IAS-USA.
Increasing Incidence of Anal Squamous Cancer in US
Nelson RA, et al. J Clin Oncol, March 18 2013 [Epub ahead print]
Slide 26 of 31
From RT Mitsuyasu, MD, at San Francisco, CA: March 29, 2013, IAS-USA.
Screening for cervical and anal dysplasia
• No national or international guideline for anal screening other than NYS DOH anal Pap screening guidelines, many recommend yearly cervical and anal PAP, with colposcopy or HRA and biopsy of any suspicious lesions and q 6m F/U for those with abnormalities noted
• Many cervical cancer screen and treat program now operating in resource-limited settings
Chiao EY et al. Clin Infect Dis 2006;43:223-33.Goldie SJ et al. JAMA 1999;282:1822-9
Slide 27 of 31
From RT Mitsuyasu, MD, at San Francisco, CA: March 29, 2013, IAS-USA.
AMC 052Percentage of participants sero- and HPV DNA-
negative to HPV 6/11/16/18
Percent HPV-negative
N=104, Median age=44
HPV 6 60
HPV 11 68
HPV 16 62
HPV 18 78
Wilkin et al. JID 2010, 202: 1246-53.
Slide 28 of 31
From RT Mitsuyasu, MD, at San Francisco, CA: March 29, 2013, IAS-USA.
HPV 6
Month 7(95% CI)
HPV 11
Month 7(95% CI)
HPV 16
Month 7(95% CI)
HPV 18
Month 7(95% CI)
Merck 020Men 16-26 yr
447(447, 503)
624(621, 684)
2402(2485, 2767)
402(416, 464)
AMC 052HIV+ MSM
357(256, 497)
525(412, 669)
1139(849, 1529)
181(136, 241)
Geometric mean titers among participants naïve to HPV 6, 11, 16, 18
Data from VRBPAC Briefing Doc Sept 9, 2009 (Table 8) and from AMC 052, Wilkin JID 2010, 202:1246-53.
Slide 29 of 31
From RT Mitsuyasu, MD, at San Francisco, CA: March 29, 2013, IAS-USA.
Treatment of AIN in HIV+• 16 wk randomized trial of imiquimod (3 X/wk), topical
5FU (2 X/wk) vs electrocautery-EC (monthly X 4) in 148 HIV+ men with AIN (57% with HGAIN)
• Subjects evaluated by HRA and bx at 4 wk and 6 mos post treatment
Richel O, et al. 19th CROI, Seattle, 2012, abst 135LB
Slide 30 of 31
From RT Mitsuyasu, MD, at San Francisco, CA: March 29, 2013, IAS-USA.
Cancer Prevention • Smoking Cessation – Highest priority
– Varenicline not hepatic met and no ART drug interaction expected
• Hepatitis B and HPV vaccination• Treat active Hepatitis C• Yearly cervical and anal (?) Paps – Gyn and HRA• Advise sun screen and avoid overexposure• Maintain high index of suspicion for cancer• Complete family history for malignancies• Breast, prostate and colon screening as per
guidelines for general population• Treat all HIV patients with HAART
Slide 31 of 31
From RT Mitsuyasu, MD, at San Francisco, CA: March 29, 2013, IAS-USA.
Summary• As HIV population ages with persistent immune
abnormalities, cancers will increase in number
• The risk of NADC is high with lung, anal, liver and HL accounting for most of this increase. The risk of colon, breast and prostate cancers are lower in HIV. HL incidence is stable overall, but may reflect lack of younger age peak, as all cases in HIV are EBV+
• As a minimum, we should conduct age/gender appropriate screening for cancer. Counsel patients on ways to reduce cancer risks
• Only through prospective clinical trials research can prevention strategies be effectively evaluated